NLRP3 inflammasome amplification across AD and PD proteinopathy
🧪 Overview
Shared mechanism across AD, PD: Misfolded protein stress activates microglial NLRP3; IL-1 beta and inflammasome signaling then amplify amyloid/tau pathology in AD and alpha-synuclein pathology with dopaminergic injury in PD, creating a shared inflammatory feed-forward loop.
Falsifiable prediction: Selective NLRP3 inhibition should reduce ASC speck formation and IL-1 beta release by at least 50%, and secondarily lower tau/alpha-synuclein seeded aggregation by at least 20% in AD and PD co-culture models.
Proposed experiment: Treat APP/PS1-tau microglia-neuron co-cultures and alpha-synuclein PD co-cultures with a selective NLRP3 inhibitor, NLRP3 knockout, and inactive analog; quantify ASC specks, caspase-1, IL-1 beta, p-tau, alpha-synuclein seeds, and neuronal survival.
Cross-disease confidence rationale: Direct AD mouse evidence plus PD alpha-synuclein inflammasome inhibition evidence.
Internal SciDEX support: SciDEX support query found 96 matching hypotheses across 8 disease labels, including 96 with debate_count > 0.
Generated by task ffd81f3a-7f04-4db1-8547-1778ce030e89 as a cross-disease mechanism synthesis, not a single-disease hypothesis renamed as multi-disease.
🧬 Mechanism
Auto-built from this analysis's top knowledge-graph edges.
graph TD
alpha_synuclein_fibrils["alpha-synuclein fibrils"] -->|activates| NLRP3_Inflammasome["NLRP3 Inflammasome"]
NLRP3["NLRP3"] -->|cross disease mech| AD["AD"]
NLRP3_1["NLRP3"] -->|cross disease mech| PD["PD"]
h_cross_synth_nlrp3_infla["h-cross-synth-nlrp3-inflammasome"] -->|proposes shared me| NLRP3_2["NLRP3"]
MCC950__NLRP3_inhibitor_["MCC950 (NLRP3 inhibitor)"] -.->|inhibits| neuroinflammation["neuroinflammation"]
style alpha_synuclein_fibrils fill:#4fc3f7,stroke:#333,color:#000
style NLRP3_Inflammasome fill:#ce93d8,stroke:#333,color:#000
style NLRP3 fill:#4fc3f7,stroke:#333,color:#000
style AD fill:#ef5350,stroke:#333,color:#000
style NLRP3_1 fill:#4fc3f7,stroke:#333,color:#000
style PD fill:#ef5350,stroke:#333,color:#000
style h_cross_synth_nlrp3_infla fill:#4fc3f7,stroke:#333,color:#000
style NLRP3_2 fill:#4fc3f7,stroke:#333,color:#000
style MCC950__NLRP3_inhibitor_ fill:#4fc3f7,stroke:#333,color:#000
style neuroinflammation fill:#4fc3f7,stroke:#333,color:#000⚖️ Evidence
🏥 Translation
🧬 3D Protein Structure — NLRP3
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for NLRP3.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
📊 Market Indicators
💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
🔮 Predictions
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| Selective NLRP3 inhibition should reduce ASC speck formation and IL-1 beta release by at least 50%, and secondarily lower tau/alpha-synuclein seeded aggregation by at least 20% in AD and PD co-culture | If this mechanism is real, then Selective NLRP3 inhibition should reduce ASC speck formation and IL-1 beta release by at least 50%, and secondarily lower tau/al | — no observation — | pending | 0.79 |
▸Metadatasource: v1_phase_c_backfill · origin_type: cross_disease_synthesis
| source | v1_phase_c_backfill |
| origin_type | cross_disease_synthesis |
| _schema_version | 1 |